Engineered pertactin variants for vaccine use

Abstract

The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis . The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.

1 . An isolated polynucleotide sequence coding for a pertactin (Prn) engineered protein, wherein said isolated polynucleotide sequence codes for up to the first 300 amino acids proximal to the N-terminal end of a given type of natural, mature Prn (PrnX300) and an amino acid sequence comprising up to the last 620 amino acids proximal to the C-terminal end of a given type of natural, mature Prn (PrnY620), resulting in an engineered PrnX300-PrnY620 pertactin, and wherein the polynucleotide sequence comprises SEQ ID NO: 4. 
     
     
         2 . The isolated polynucleotide sequence according to  claim 1 , wherein said PrnX300 amino acid sequence comprises Prn sequences from the  Bordetella  genera. 
     
     
         3 . The isolated polynucleotide sequence according to  claim 2 , wherein said PrnX300 amino acid sequence comprises Prn sequences from  B. pertussis  or  B. parapertussis.    
     
     
         4 . The isolated polynucleotide sequence according to  claim 3 , wherein said PrnX300 amino acid sequence comprises Prn sequences from Prn1, Prn2 and Prn3 of  B. pertussis.    
     
     
         5 . The isolated polynucleotide sequence according to  claim 1 , wherein said PrnY620 amino acid sequence comprises Prn sequences from the  Bordetella  genera. 
     
     
         6 . The isolated polynucleotide sequence according to  claim 5 , wherein said PrnY620 amino acid sequence comprises Prn sequences from  B. pertussis  or  B. parapertussis.    
     
     
         7 . The isolated polynucleotide sequence according to  claim 3 , wherein said PrnY620 amino acid sequence comprises Prn sequences from Prn1, Prn2 and Prn3 of  B. pertussis.    
     
     
         8 . The isolated polynucleotide sequence according to  claim 1 , wherein said polynucleotide sequence codes for a polypeptide comprising any possible combination of Prn of any type in the format PrnX300-PrnY620. 
     
     
         9 . The isolated polynucleotide sequence according to  claim 1 , wherein said PrnX300 and PrnY620 amino acid sequences are coupled adjacently, or by means of IDNATWVMTDN or IDNATWVMTDNIDNATWVMTDN amino acid sequences. 
     
     
         10 . The isolated polynucleotide sequence according to  claim 1 , wherein said PrnX300 and PrnY620 amino acid sequences are devoid of repetitive sequences, and more precisely, devoid of GGXXP and PQP repetitive sequences from Prn regions R1 and R2. 
     
     
         11 . The isolated polynucleotide sequence according to  claim 1 , wherein said PrnX300 and PrnY620 amino acid sequences additionally comprise peptides with T helper epitopes. 
     
     
         12 . (canceled) 
     
     
         13 . The isolated polynucleotide sequence according to  claim 1 , that has an optimized codon usage for optimal expression in bacteria, yeast, insect or mammalian cells. 
     
     
         14 . A pharmaceutical composition comprising a polynucleotide sequence according to  claim 1 . 
     
     
         15 . A pharmaceutical composition according to  claim 14 , wherein said pharmaceutical composition generates effective humoral and cellular immune responses against  B. pertussis.    
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . An isolated expression vector comprising an isolated polynucleotide sequence according to  claim 1 , wherein said sequence codes for engineered Prn molecules. 
     
     
         19 . (canceled) 
     
     
         20 . A method to detect  B. pertussis  or  B. parapertussis  infections, comprising the use of a polypeptide sequence according to  claim 1 . 
     
     
         21 . A diagnostic kit for detection of  B. pertussis  or  B. parapertussis , wherein said diagnostic kit comprises a polynucleotide sequence according to  claim 1 . 
     
     
         22 . The isolated polynucleotide sequence according to  claim 11 , wherein said peptides are obtained from Diphtheria, Tetanus, HBV, Poliovirus, Vaccinia, HIV or Influenza virus.